Erlotinib - Astellas Pharma/Roche
Alternative Names: CP-358774; CP-358774-01; Erlotinib hydrochloride; NSC-718781; OSI-774; R-1415; RG-1415; RO-508231; Ro50-8231; TarcevaLatest Information Update: 05 Nov 2023
At a glance
- Originator OSI Pharmaceuticals
- Developer Alliance for Clinical Trials in Oncology; Astellas Pharma; Chugai Pharmaceutical; Eli Lilly and Company; European Thoracic Oncology Platform; Finnish Lung Cancer Group; Genentech; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Novartis; OSI Pharmaceuticals; Polyphenon Pharma; Roche; SCRI Development Innovations; Takeda Oncology; University of Texas M. D. Anderson Cancer Center; Wake Forest University School of Medicine
- Class Alkynes; Antineoplastics; Quinazolines; Skin disorder therapies; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer; Pancreatic cancer
- Phase III Ependymoma; Head and neck cancer; Mouth neoplasm
- Phase II Bladder cancer; Brain metastases; Glioblastoma; Gynaecological cancer; Neuroendocrine tumours; Squamous cell cancer
- Phase I/II Colorectal cancer; Myelodysplastic syndromes; Solid tumours
- No development reported Anaplastic astrocytoma; Breast cancer; Bronchiolo-alveolar adenocarcinoma; Cancer metastases
- Discontinued Liver cancer
Most Recent Events
- 07 Dec 2022 University of Texas M. D. Anderson Cancer Center and Millenium Pharmaceuticals complete a phase I trial in Solid tumours, Non-small cell lung cancer, Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02942095)
- 26 Apr 2022 No development reported - Phase-III for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Bulgaria, Italy, Germany, Belgium, Sweden, USA (PO)
- 19 May 2021 The MD Anderson Cancer Center and Genentech completes a phase II trial for Liver cancer (Inoperable/Unresectable, Combination therapy, Second-line therapy or greater) in USA (NCT01180959)